Elite in Smoldering Multiple Myeloma

Joan Bargay

Palma, PM, ES 
Elite in Smoldering Multiple Myeloma
Palma, PM, ES 
OverviewLocationsClinical Research

Overview

Joan Bargay practices in Palma, Spain. Ms. Bargay is rated as an Elite expert by MediFind in the treatment of Smoldering Multiple Myeloma. Her top areas of expertise are Smoldering Multiple Myeloma, Multiple Myeloma, Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Bone Marrow Transplant.

Her clinical research consists of co-authoring 95 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 7 articles in the study of Smoldering Multiple Myeloma.

Gender
Female

Locations

Palma, PM 07198, Spain
Other Locations
Porto Do Son, GA, Spain

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

An Open Label, Multicenter, Phase II Study of Belantamab Mafodotin in Combination With VRd for the Treatment of Newly Diagnosed Transplant Eligible Multiple Myeloma Patients
An Open Label, Multicenter, Phase II Study of Belantamab Mafodotin in Combination With VRd for the Treatment of Newly Diagnosed Transplant Eligible Multiple Myeloma Patients
Enrollment Status: Active_not_recruiting
Publish Date: December 17, 2025
Intervention Type: Drug, Procedure
Study Drugs: Belantamab Mafodotin, Bortezomib, Lenalidomide, Dexamethasone
Study Phase: Phase 2
A Randomized Phase III, Multicentre, Open Label Clinical Trial Comparing Azacitidine Plus Pevonedistat Versus Azacitidine in Older/Unfit Patients With Newly Diagnosed Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Chemotherapy
A Randomized Phase III, Multicentre, Open Label Clinical Trial Comparing Azacitidine Plus Pevonedistat Versus Azacitidine in Older/Unfit Patients With Newly Diagnosed Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: March 17, 2025
Intervention Type: Drug
Study Drugs: Pevonedistat, Azacitidine
Study Phase: Phase 3
View 1 Less Clinical Trial

95 Total Publications

From Clinical Perception to Implicit Bias: Understanding Personality Traits in Lymphoma Patients.
From Clinical Perception to Implicit Bias: Understanding Personality Traits in Lymphoma Patients.
Journal: Cancers
Published: March 31, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Bargay's expertise for a condition
ConditionClose
View All 9 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile